Panacea Biotec Ltd
NSE:PANACEABIO

Watchlist Manager
Panacea Biotec Ltd Logo
Panacea Biotec Ltd
NSE:PANACEABIO
Watchlist
Price: 433.25 INR 0.97% Market Closed
Market Cap: 26.5B INR
Have any thoughts about
Panacea Biotec Ltd?
Write Note

Panacea Biotec Ltd
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Panacea Biotec Ltd
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
Panacea Biotec Ltd
NSE:PANACEABIO
Note Receivable
â‚ą85.1m
CAGR 3-Years
27%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
Note Receivable
â‚ą7.1m
CAGR 3-Years
-5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Transgene Biotek Ltd
BSE:526139
Note Receivable
â‚ą1.3B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Z
Zenotech Laboratories Ltd
BSE:532039
Note Receivable
â‚ą53.8m
CAGR 3-Years
47%
CAGR 5-Years
50%
CAGR 10-Years
6%
Hester Biosciences Ltd
NSE:HESTERBIO
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biocon Ltd
NSE:BIOCON
Note Receivable
â‚ą9.1B
CAGR 3-Years
47%
CAGR 5-Years
40%
CAGR 10-Years
12%
No Stocks Found

Panacea Biotec Ltd
Glance View

Market Cap
26.5B INR
Industry
Biotechnology

Panacea Biotec Ltd. is a biotechnology company, which is engaged in the business of research, development, manufacture, and marketing of vaccines and pharmaceutical formulations. The company is headquartered in New Delhi, Delhi. The Company’s research areas include new chemical entities (NCE), new biological entities (NBE) novel drug delivery system (NDDS) based pharmaceutical formulations, novel peptides and human monoclonal antibodies and vaccine development. The Company’s product portfolio includes pain management, diabetes & cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, gastrointestinal care products and vaccines. The Company’s subsidiaries include Panacea Biotec Pharma Limited, Panacea Biotec (International) SA, PanEra Biotec Private Limited and Meyten Realtech Private Limited.

PANACEABIO Intrinsic Value
178.94 INR
Overvaluation 59%
Intrinsic Value
Price

See Also

What is Panacea Biotec Ltd's Note Receivable?
Note Receivable
85.1m INR

Based on the financial report for Sep 30, 2024, Panacea Biotec Ltd's Note Receivable amounts to 85.1m INR.

What is Panacea Biotec Ltd's Note Receivable growth rate?
Note Receivable CAGR 5Y
22%

Over the last year, the Note Receivable growth was 5%. The average annual Note Receivable growth rates for Panacea Biotec Ltd have been 27% over the past three years , 22% over the past five years .

Back to Top